Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is a pioneering company in the field of artificial intelligence powered synthetic biology, with a strong focus on the potential of proteins as the next generation of therapeutics. With its lead product candidate ABS-201 showing promising results in early studies and a partnership with Eli Lilly, Absci is well-positioned for success in developing novel biologics. The company's diverse pipeline and partnerships provide additional potential for growth, ensuring it remains a strong contender in the competitive landscape of ML/AI drug discovery.

Bears say

Absci is conducting trials on their lead product candidate, ABS-201, to determine the optimal dosing for patient-friendly administration, with interim PK data suggesting a half-life of ≥65 days and the potential for 2-3 doses over a six-month period. While initial safety data is favorable, the lack of efficacy data and potential for more frequent administration may affect the drug's commercial viability and future profitability.

Absci Corp (ABSI) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.